<DOC>
	<DOCNO>NCT00613509</DOCNO>
	<brief_summary>Primary objective : To evaluate clinical activity vaccine regimen , indicate progression-free survival versus clinical activity reference treatment . Secondary objective : Safety : To describe safety profile treatment group . Efficacy : To determine objective clinical response patient treatment group : complete response partial response .</brief_summary>
	<brief_title>Study Multi-Antigen Therapeutic Vaccine Patients With Metastatic Melanoma</brief_title>
	<detailed_description>Eligible participant randomize receive either vaccine treatment consist series multi-antigen melanoma vaccine GM-CSF injection , follow high-dose IFN-α2b high-dose IFN-α2b .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<criteria>Inclusion Criteria : A pathologically confirm diagnosis malignant melanoma least one measurable metastatic lesion minimum lesion size 20 mm , base radiological assessment ( 10 mm assess spiral compute tomography [ CT ] scan ) per Response Evaluation Criteria Solid Tumors ( RECIST ) criterion ( Stages IIIc , IVa , IVb , accord American Joint Committee Cancer ( AJCC ) stag system melanoma ) . Cutaneous metastasis ( assessed physical examination ) must least 10 mm . CT scan magnetic resonance imaging ( MRI ) require rule brain metastasis . Patients receive prior treatment metastatic disease must objective evidence disease progression . Aged ≥ 18 year day inclusion IRBapproved inform consent form sign Able attend schedule visit comply trial procedure For woman , inability bear child negative serum pregnancy test For woman childbearing potential , use effective method contraception abstinence study least 4 week last study treatment Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 life expectancy least 6 month . Adequate hematologic , hepatic , renal function ( predefined laboratory value ) . Fully recover surgery , applicable . Exclusion Criteria : Receipt two previous therapy metastatic melanoma . Receipt chemotherapy another therapy metastatic melanoma within last four week Receipt adjuvant interferon therapy within last six month Concurrent receipt radiotherapy metastatic disease , unless palliative purpose Participation another clinical trial within four week precede first trial treatment Planned participation another clinical trial present trial period Known Human Immunodeficiency Virus ( HIV ) infection hepatitis B ( Ag HBs ) hepatitis C seropositivity Presence active autoimmune disease ( exclude vitiligo ) Systemic hypersensitivity bovine product vaccine component , include egg product Neomycin ( use prepare vaccine ) , history lifethreatening reaction granulocytemacrophage colony stimulate factor ( GMCSF ) interferon ( IFN ) α2b Current alcohol drug addiction may interfere ability comply trial procedure Significant comorbid medical condition , include preexist renal disease , cirrhosis , major depression , estimation investigator would preclude safe participation study accurate interpretation data . A calculated glomerular filtration rate ( GFR ) &lt; 60 mL/min ( base CockroftGault formula ) . Previous receipt modify canarypox virus ( ALVAC ) base vaccine .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Melanoma , Cancer</keyword>
</DOC>